Consumo de fármacos utilizados en el tratamiento del dolor musculoesquético en una cohorte de trabajadores manuales de Zaragoza

Elena Maria Gaspar Calvo, M� Jesús Lallana Álvarez, Sara Malo Fumanal
2020 Revista de la Sociedad Española del Dolor  
Correspondencia: Elena Gaspar Calvo egaspar@salud.aragon.es Gaspar Calvo E, Lallana Álvarez MJ, Malo S. Consumo de fármacos utilizados en el tratamiento del dolor musculoesquelético en una cohorte de trabajadores manuales de Zaragoza (España). Rev Soc Esp Dolor. 2020;27(3):150-159 Consumo de fármacos utilizados en el tratamiento del dolor musculoesquelético en una cohorte de trabajadores manuales de Zaragoza (España) Drug consumption used for musculoskeletal pain treatment in a cohort of
more » ... llar workers in Zaragoza (Spain) ABSTRACT Introduction: The high prevalence of musculoskeletal diseases (MSDs) in certain populaion groups may cause a high consumption of non steroideal antiinflamatory drugs (NSAIDs). The present study aims to identify the continuous consumers of NSAIDs in a cohort of workers, who mainly perform manual tasks, analyzing the use of other drugs prescribed for the treatment of musculoskeletal pain (MSP). Material and methods: Observational retrospective study. It has been analyzed data of all subjects, included on the AWHS (Aragon Workers Health Study) cohort, who received at least one NSAID prescription during 2016. It has been calculated the rate of use of NSAID, as well as the number of DDD per 1000 inhabitants per day (DHD). It has been identified continuous consumers, as those who used 182 defined daily dose (DDD) or more. For this group, it has been analyzed all prescriptions including other drugs used to treat MSP. Results: The rate of use of NSAIDs in the AWHS cohort in 2016 was 41.6% (95% CI: 40.1%-42.7%), being higher in women (47.0%, 95% CI: 41.9%-52.1%). 5.7% of NSAID users were continuous consumers. Among them, etoricoxib was the most used NSAIDs (4,9 DHD), followed by ibuprofen (4,0 DHD). Refering to other drugs prescribed for MSP, the prescription rate of tramadol for continuous consumers was
doi:10.20986/resed.2020.3749/2019 fatcat:6sroxy5uibdita6nvfm6nesywe